Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1924

1.

Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.

Fiorillo M, Sotgia F, Sisci D, Cappello AR, Lisanti MP.

Oncotarget. 2017 Mar 2;8(12):20309-20327. doi: 10.18632/oncotarget.15852.

2.

S100β as a serum marker in endocrine resistant breast cancer.

Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS.

BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2.

3.

MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer.

Han SH, Kim HJ, Gwak JM, Kim M, Chung YR, Park SY.

J Breast Cancer. 2017 Mar;20(1):35-44. doi: 10.4048/jbc.2017.20.1.35. Epub 2017 Mar 24.

4.

Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers.

Beh CY, How CW, Foo JB, Foong JN, Selvarajah GT, Rasedee A.

Drug Des Devel Ther. 2017 Mar 14;11:771-782. doi: 10.2147/DDDT.S123939. eCollection 2017.

5.

[Primary large cell neuroendocrine carcinoma of the breast: a rare tumor in humans].

Safini F, Bouchbika Z, Bennani Z, Belkheiri S, Attar HE, Benchakroun N, Jouhadi H, Tawfiq N, Sahraoui S, Benider A.

Pan Afr Med J. 2016 Nov 29;25:205. doi: 10.11604/pamj.2016.25.205.10366. eCollection 2016. French.

6.

Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.

Yamaguchi N, Nakayama Y, Yamaguchi N.

J Biol Chem. 2017 May 19;292(20):8136-8148. doi: 10.1074/jbc.M116.763276. Epub 2017 Mar 7.

7.

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen.

Jeon SJ, Lee JI, Lee M, Kim HS, Kim JW, Park NH, Song YS.

Obstet Gynecol Sci. 2017 Jan;60(1):26-31. doi: 10.5468/ogs.2017.60.1.26. Epub 2017 Jan 19.

8.

BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.

Cheng S, Castillo V, Welty M, Alvarado M, Eliaz I, Temm CJ, Sandusky GE, Sliva D.

BMC Complement Altern Med. 2017 Feb 16;17(1):115. doi: 10.1186/s12906-017-1621-7.

9.

Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.

Park WC.

J Breast Cancer. 2016 Dec;19(4):341-348. doi: 10.4048/jbc.2016.19.4.341. Epub 2016 Dec 23. Review.

10.

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report.

Ballatore Z, Pistelli M, Battelli N, Pagliacci A, De Lisa M, Berardi R, Cascinu S.

BMC Res Notes. 2016 Nov 28;9(1):497.

11.

Feature of amenorrhea in postoperative tamoxifen users with breast cancer.

Kim H, Han W, Ku SY, Suh CS, Kim SH, Choi YM.

J Gynecol Oncol. 2017 Mar;28(2):e10. doi: 10.3802/jgo.2017.28.e10. Epub 2016 Oct 27.

13.

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.

Hong JH, Ha KS, Jung YH, Won HS, An HJ, Lee GJ, Kang D, Park JC, Park S, Byun JH, Suh YJ, Kim JS, Park WC, Jung SS, Park IY, Chung SM, Woo IS.

Cancer Res Treat. 2016 Oct;48(4):1389-1398. Epub 2016 Apr 11.

15.

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S.

Oncogene. 2017 Apr 20;36(16):2286-2296. doi: 10.1038/onc.2016.382. Epub 2016 Oct 17.

16.

Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.

Donneyong MM, Bykov K, Bosco-Levy P, Dong YH, Levin R, Gagne JJ.

BMJ. 2016 Sep 30;354:i5014. doi: 10.1136/bmj.i5014.

17.

Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.

Wangchinda P, Ithimakin S.

World J Surg Oncol. 2016 Aug 24;14(1):223. doi: 10.1186/s12957-016-0988-0.

18.

Tamoxifen Resistance: Emerging Molecular Targets.

Rondón-Lagos M, Villegas VE, Rangel N, Sánchez MC, Zaphiropoulos PG.

Int J Mol Sci. 2016 Aug 19;17(8). pii: E1357. doi: 10.3390/ijms17081357. Review.

19.

CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway.

Wu ST, Sun GH, Cha TL, Kao CC, Chang SY, Kuo SC, Way TD.

J Biomed Sci. 2016 Aug 15;23(1):60. doi: 10.1186/s12929-016-0275-y.

20.

Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.

Farias AJ, Hansen RN, Zeliadt SB, Ornelas IJ, Li CI, Thompson B.

J Manag Care Spec Pharm. 2016 Aug;22(8):969-78. doi: 10.18553/jmcp.2016.22.8.969.

Supplemental Content

Loading ...
Support Center